Double-target chimeric antigen receptor, CAR-T cell and application of CAR-T cell

By designing dual-target chimeric antigen receptors, combining EGFRvIII and GRP78 scFv, CAR-T cells were constructed, and the problems of EGFRvIII expression heterogeneity and antigen escape were solved, significantly improving the killing ability and cells of brain glioblastoma Factor secretion ability achieves stronger anti-tumor activity.

CN119020381AInactive Publication Date: 2024-11-26SHANGHAI XINGRUIYIDA BIOTECHNOLOGY CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411505699.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-28
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the prior art, EGFRvIII expression heterogeneity affects the efficacy of CAR-T cells targeting EGFRvIII antigen, and the single-target CAR-T cell antigen is likely to escape, and no CAR with dual-target targets is used for Related reports on the treatment of brain glioblastoma.

Method used

Design a dual-target chimeric antigen receptor, including EGFRvIII scFv and GRP78 scFv, through CD8 signal peptide, Linker, GRP78 scFv, CD8 Hinge region, CD8 transmembrane region, CD28 costimulatory region, 4-1BB costimulatory region , the CD3ζ signaling region was connected to construct dual-target CAR-T cells to target two antigens EGFRvIII and GRP78.

Benefits of technology

By targeting the two antigens EGFRvIII and GRP78, the target specificity is enhanced, and the problem of EGFRvIII expression heterogeneity is overcome, and the cytokine secretion ability and anti-tumor activity of CAR-T cells are significantly improved. In particular, the optimized GRP78 scFv sequence has been significantly improved. The killing rate of T cells on U87 MG cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020381A_ABST
    Figure CN119020381A_ABST
Patent Text Reader

Abstract

The invention provides a double-target chimeric antigen receptor, a CAR-T cell and application of the double-target chimeric antigen receptor and the CAR-T cell, and belongs to the technical field of hybrid peptides. The double-target chimeric antigen receptor comprises EGFRvIII scFv and GRP78 scFv; the nucleotide sequence of the EGFRvIII scFv is as shown in SEQ ID NO. 2; and the nucleotide sequence of the GRP78 scFv is as shown in SEQ ID NO. 4. According to the invention, by targeting two antigen targets of EGFRvIII and GRP78, the targeting specificity is enhanced, and the ability of CAR-T cells to kill glioblastoma is enhanced. Compared with a single-target CAR-T cell (EGFRvIII-CAR-T cell or GRP78-CAR-T cell), the T cell modified by the double-target chimeric antigen receptor provided by the invention has better cell factor secretion capability and better killing effect on tumor cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a dual-target chimeric antigen receptor, a CAR-T cell and applications thereof, and belongs to the technical field of hybrid peptides. Background Art

[0002] Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system. It is called the "new king of cancer" because of its extremely high malignancy. According to reports, after the standard treatment of GBM patients, such as maximum safe tumor resection and postoperative synchronous radiotherapy and chemotherapy, the median survival time is only about 15 months, the recurrence rate is as high as 90%, and the 5-year survival rate is less than 5%. Therefore, it is particularly urgent to develop effective methods to treat glioblastoma.

[0003] The antitumor activity of chimeric antigen receptor T cells (CAR-T cells) against solid tumors is hampered by several factors, including the expansion and persistence of CAR-T cells, the immunosuppressive tumor microenvironment (TME), and the heterogeneous expression of limited targetable tumor antigens.

[0004] Epidermal growth factor receptor type III mutant (EGFRvⅢ) is a tumor-specific antigen with a high expression rate in malignant tumors such as glioblastoma. It is closely related to the occurrence and development of tumors and is an ideal molecular target for tumor targeted therapy. Current clinical trials have shown that T cells modified with chimeric antigen receptors targeting EGFRvⅢ are effective in treating brain glioblastoma.

[0005] Cell surface glucose-regulated protein 78 (GRP78), a key unfolded protein response (UPR) regulator, is normally located in the endoplasmic reticulum (ER) and is overexpressed in malignant tumors and ectopically localized to the surface of cancer cells in response to elevated ER stress. Expression profiles of the GPRP78 gene showed that among different cancer types, highly malignant and aggressive glioblastoma had the highest expression of GRP78. In addition, as a common essential gene, GRP78 is less prone to antigen loss, and the fact that cell surface translocation of GRP78 in tumor cells is driven by multiple mechanisms reduces the possibility of immune escape.

[0006] CN106967685B discloses transgenic lymphocytes co-expressing anti-EGFRvIII chimeric antigen receptors and immune checkpoint inhibitory molecules and their uses. The patent proposes a construct of a nucleic acid molecule carrying a silent cell immune checkpoint (CTLA4, PD-1 or CBL-B) and a nucleic acid molecule encoding a chimeric antigen receptor, and a transgenic lymphocyte formed after the construct is introduced, wherein the chimeric antigen receptor encoded by the construct specifically binds to the antigen EGFRvIII.

[0007] CN115957335B discloses a mononuclear extracellular vesicle analog based on chimeric antigen receptor modification, a preparation method and an application. This patent provides a mononuclear extracellular vesicle analog based on chimeric antigen receptor modification (EGFRvIII), a preparation method and an application thereof, which solves the problem that chemotherapy drugs are difficult to target and kill glioblastoma due to the bottleneck of the blood-brain barrier.

[0008] The CAR-T cells involved in CN106967685B and CN115957335B are both antigen chimeric receptors that specifically recognize EGFRvIII antigen. Due to the heterogeneity of EGFRvIII expression, the efficacy of CAR-T cells targeting EGFRvIII antigen against GBM tumors will be affected. Moreover, these two patents are single-target CARs that specifically recognize EGFRvIII antigen, and the possibility of antigen escape is also relatively high.

[0009] There are currently no reports on the use of CAR with dual targets of EGFRvⅢ and GRP78 for the treatment of glioblastoma. Summary of the invention

[0010] In view of the shortcomings of the prior art, the present invention provides a dual-target chimeric antigen receptor, CAR-T cells and applications thereof to achieve the following invention objectives: the dual-target chimeric antigen receptor enhances targeting specificity and overcomes the problem of EGFRvIII expression heterogeneity by targeting two antigen targets, EGFRvⅢ and GRP78; the T cells modified with the dual-target chimeric antigen receptor have significantly improved cytokine secretion ability and anti-tumor activity.

[0011] In order to solve the above technical problems, the present invention adopts the following technical solutions: A dual-target chimeric antigen receptor, the dual-target chimeric antigen receptor comprising EGFRvⅢ scFv and GRP78 scFv; the nucleotide sequence of the EGFRvⅢ scFv is shown in SEQ ID NO.2; the nucleotide sequence of the GRP78 scFv is shown in SEQ ID NO.4.

[0012] The dual-target chimeric antigen receptor is connected in sequence by the following modules: CD8 signal peptide, EGFRvⅢ scFv, Linker, GRP78 scFv, CD8 Hinge region, CD8 transmembrane region, CD28 co-stimulatory region, 4-1BB co-stimulatory region, and CD3ζ signal transduction region.

[0013] The nucleotide sequence of the CD8 signal peptide is shown in SEQ ID NO.1; the nucleotide sequence of the Linker is shown in SEQ ID NO.3; the nucleotide sequence of the CD8 Hinge region is shown in SEQ ID NO.5; the nucleotide sequence of the CD8 transmembrane region is shown in SEQ ID NO.6; the nucleotide sequence of the CD28 co-stimulatory region is shown in SEQ ID NO.7; the nucleotide sequence of the 4-1BB co-stimulatory region is shown in SEQ ID NO.8; and the nucleotide sequence of the CD3ζ signaling region is shown in SEQ ID NO.9.

[0014] A dual-target CAR-T cell, wherein the CAR-T cell is obtained from the chimeric antigen receptor modified T cell.

[0015] The chimeric antigen receptor is used in the preparation of medicines for treating glioblastoma.

[0016] The use of the CAR-T cells in the preparation of medicines for treating glioblastoma.

[0017] Compared with the prior art, the present invention achieves the following beneficial effects: (1) The present invention targets two antigen targets, EGFRvⅢ and GRP78, to enhance targeting specificity, overcome the problem of EGFRvIII expression heterogeneity, and can simultaneously recognize two antigens (GRP78, EGFRvⅢ), which can better eliminate tumor cells, reduce the antigen escape phenomenon caused by tumor heterogeneity, and further enhance the ability of CAR-T cells to kill glioblastoma. Compared with single-target CAR-T cells (EGFRvⅢ-CAR-T cells or GRP78-CAR-T cells), the dual-target chimeric antigen receptor-modified T cells of the present invention have better cytokine secretion ability and tumor cell killing effect.

[0018] (2) The present invention performs codon optimization on the nucleotide sequence of GRP78 scFv, which can significantly improve the ability of CAR-T cells to secrete cytokines and the killing rate of tumor cells, making them have stronger anti-tumor activity. The chimeric antigen receptor-modified T cells prepared by the present invention using the optimized nucleotide sequence of GRP78 scFv have a killing rate of 97.8% on U87 MG cells, while the chimeric antigen receptor-modified T cells prepared by using the unoptimized nucleotide sequence of GRP78 scFv have a killing rate of only 83.5% on U87 MG cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 It is the flow cytometric graph of the positive expression rate of T cells; A is a flow cytometric graph of the CD3+ positive expression rate of T cells; B is a flow cytometric graph of the CD3+CD56+ double positive expression rate of T cells; Figure 2 Flow cytometric graph of transfection efficiency of EGFRvⅢ-GRP78-CAR-T cells; Figure 3 is a bar graph of cytokine secretion in Example 4; Figure 4 It is a bar graph of the cell killing rate in Example 5. DETAILED DESCRIPTION

[0020] Example 1 Construction of EGFRvⅢ and GRP78 dual-target CAR expression vector The modules and nucleotide sequences of the EGFRvⅢ and GRP78 dual-target CAR expression vector are as follows: (1) CD8 signal peptide (SEQ ID NO.1) (2) EGFRvIII scFv (SEQ ID NO.2) (3)Linker (SEQ ID NO.3) (4) GRP78 scFv (SEQ ID NO.4) (5) CD8 Hinge region (SEQ ID NO.5) (6) CD8 transmembrane region (SEQ ID NO.6) (7) CD28 co-stimulatory region (SEQ ID NO.7) (8) 4-1BB co-stimulatory region (SEQ ID NO.8) (9) CD3ζ signal transduction region (SEQ ID NO.9) The above sequences were connected in sequence, and the entire expression frame was synthesized by Sangon Biotechnology (Shanghai) Co., Ltd. and inserted into the standard vector pUC57 to obtain pUC-EGFRvⅢ-GRP78-CAR, which was transformed into E. coli (DH5α). After correct sequencing, the recombinant plasmid was extracted from the positive clone and named EGFRvⅢ-GRP78-CAR.

[0021] The above GRP78 scFv was replaced with an unoptimized GRP78 scFv, and a recombinant plasmid was constructed according to the above method, which was named EGFRvⅢ-GRP78 unoptimized-CAR. The nucleotide sequence of the unoptimized GRP78 scFv is shown in SEQ ID NO.10.

[0022] SEQ ID NO.3 and SEQ ID NO.4 were omitted, and the nucleotide sequences of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, and SEQ ID NO.9 were connected in sequence. A recombinant plasmid was constructed according to the above method and named EGFRvⅢ-CAR.

[0023] SEQ ID NO.2 and SEQ ID NO.3 were omitted, and the nucleotide sequences of SEQ ID NO.1, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, and SEQ ID NO.9 were connected in sequence. A recombinant plasmid was constructed according to the above method and named GRP78-CAR.

[0024] The concentration of the above recombinant plasmids was 1.0 μg / μL.

[0025] Example 2 Lentivirus packaging and titer detection (1) Inoculate the lentiviral packaging cell line 293T in DMEM medium containing 10 vol% FBS and culture in a culture dish at 37°C and 5% CO2. Prepare for transfection when the adhesion rate reaches 70%.

[0026] (2) Take a sterile 1.5 ml EP tube and prepare the reaction system according to the following components: serum-free DMEM: 3 mL; EGFRvⅢ-GRP78-CAR recombinant plasmid: 10 μg; GM easyTM Lentiviral Mix (lentiviral packaging auxiliary plasmid mixture): 10 μL (10 μg); HG Transgene TM Reagent (high-efficiency transfection reagent): 60 μL. After mixing, let it stand at room temperature for 20 minutes, then evenly add it to a culture dish containing 293T cells and place it in a CO2 incubator for culture.

[0027] (3) 12 hours after transfection, carefully aspirate the cell culture medium and discard it in a waste liquid cup containing disinfectant. Then add 15 mL of DMEM medium containing 10 vol% serum to the culture dish. After continuing to culture for 48 hours, aspirate the cell supernatant into a 50 mL centrifuge tube and centrifuge at 4°C, 500 g for 5 min. Filter the supernatant with a 0.45 μm filter to obtain the virus solution, which is then transferred to a new centrifuge tube.

[0028] (4) The above virus liquid was concentrated to obtain the EGFRvⅢ-GRP78-CAR recombinant lentivirus. After the titer was detected, it was stored in a -80°C low-temperature refrigerator for future use.

[0029] The titer of EGFRvⅢ-GRP78-CAR recombinant lentivirus was 5.21×10 7 pfu / mL.

[0030] The recombinant plasmids EGFRvⅢ-GRP78 unoptimized-CAR, EGFRvⅢ-CAR, and GRP78-CAR were packaged with lentiviruses according to the above method, and the recombinant lentiviruses of EGFRvⅢ-GRP78 unoptimized-CAR, EGFRvⅢ-CAR, and GRP78-CAR were obtained, and the detection titers were 5.22×10 7 pfu / mL, 5.16×10 7 pfu / mL and 4.96×10 7 pfu / mL; the titer of the above recombinant lentivirus was adjusted to 5×10 7 pfu / mL.

[0031] Example 3 Preparation of CAR-T cells (1) T cell culture 50 mL of the patient's autologous peripheral blood was taken and separated with TBD sample density separation fluid (purchased from Tianjin Haoyang Huake Biological). PMBCs were induced and cultured for 24 hours with DMEM (purchased from CORNING, 88-551-CM) containing 1000 IU / mL recombinant interferon α2a (purchased from Shenyang Sansheng Pharmaceutical). 1000 IU / mL (final concentration) of recombinant IL-2 (purchased from Shenyang Sansheng Pharmaceutical), 50 ng / mL (final concentration) of OKT-3 and 5% (volume ratio) of the patient's autologous plasma were added to induce and continue to culture for 24 hours. The liquid was doubled every two days, and the positive expression rate of CD3+ and CD56+ in T cells was detected by flow cytometry on the 14th day (CD3-FITC, CD16 / CD56-PE antibodies were purchased from BECKMAN, A07735). When the CD3+ positive expression rate was >80% and the CD3+CD56+ double positive expression rate was >20%, T cell induction was considered successful and the cells were retained for virus infection.

[0032] The results are as follows Figure 1 As shown, the CD3+ positive expression rate of T cells was 97.6%, and the CD3+CD56+ double positive expression rate was 27.1%.

[0033] (2) Recombinant lentivirus infection of T cells The EGFRvⅢ-GRP78-CAR recombinant lentivirus prepared above was taken out from -80℃, and the T cells were resuspended after thawing to obtain a cell suspension, which was added to a 6-well plate, 1 mL per well, so that the ratio of the number of virus particles to the number of T cells was 50:1. After culturing in a 37℃, 5% CO2 incubator for 6 hours, 1 mL of T cell culture medium was added to each well and continued to be cultured. After a total infection time of 1 week, the obtained EGFRvⅢ-GRP78-CAR-T cells were detected, and the expression of chimeric antigen receptors was detected by flow cytometry.

[0034] Figure 2 The expression of the EGFRvⅢ-GRP78-CAR vector constructed by the present invention on the surface of T cells was detected by flow cytometry. The results showed that the transfection efficiency of the EGFRvⅢ-GRP78-CAR-T cells constructed by the present invention was 38.6%.

[0035] EGFRvⅢ-GRP78 unoptimized-CAR, EGFRvⅢ-CAR, and GRP78-CAR recombinant lentiviruses were used to infect T cells according to the above method to obtain EGFRvⅢ-GRP78 unoptimized-CAR-T cells, EGFRvⅢ-CAR-T cells, and GRP78-CAR-T cells, with transfection efficiencies of 39.5%, 39.2%, and 38.6%, respectively.

[0036] Table 1 Transfection efficiency of CAR-T cells

[0037] Example 4 Detection of cytokine secretion by co-culture of CAR-T cells and target cells U87 MG cells (glioblastoma cell line) were used as target cells, and the EGFRvⅢ-GRP78-CAR-T cells, EGFRvⅢ-GRP78 unoptimized-CAR-T cells, EGFRvⅢ-CAR-T cells, GRP78-CAR-T cells and untransfected T cells (control) prepared in Example 3 were used as effector cells, and the effector cells (1×10 5 / well) and target cells (1×10 5 / well) were inoculated into 96-well plates, 100μL / well was mixed and cultured, three replicates per group were placed in a 37℃, 5% CO2 incubator for 48h, and the culture supernatant was collected and the cytokine (IFN-γ, IL-2) secretion was detected by ELSA method.

[0038] The specific groups are as follows: Experimental group A: EGFRvⅢ-GRP78-CAR-T cells were co-cultured with U87 MG cells; Experimental group B: EGFRvⅢ-GRP78 unoptimized-CAR-T cells co-cultured with U87 MG cells; Experimental group C: EGFRvⅢ-CAR-T cells were co-cultured with U87 MG cells; Experimental group D: GRP78-CAR-T cells were co-cultured with U87 MG cells; Control group: T cells were co-cultured with U87 MG cells.

[0039] ELISA results showed (see Figure 3 and Table 2): The amount of cytokines (IFN-γ, IL-2) secreted by the experimental group cells was significantly higher than that of the control group, and there was a significant difference; compared with the single-target CAR-T cells (experimental groups C and D), the dual-target CAR-T cells (experimental groups A and B) had a stronger ability to secrete cytokines.

[0040] In addition, the dual-target EGFRvⅢ-GRP78-CAR-T cells (experimental group A) provided by the present invention have a higher ability to secrete cytokines than EGFRvⅢ-GRP78 unoptimized-CAR-T cells (experimental group B), which indicates that the nucleotide sequence of GRP78 scFv can enhance the immune response of CAR-T cells after codon optimization, causing them to release more cytokines, thereby improving the functional activity of CAR-T cells.

[0041] Table 2 Cytokine secretion

[0042] Example 5 Detection of cell killing rate U87 MG cells (glioblastoma cell line) were used as target cells, and EGFRvⅢ-GRP78-CAR-T cells, EGFRvⅢ-GRP78 unoptimized-CAR-T cells, EGFRvⅢ-CAR-T cells, GRP78-CAR-T cells, and untransfected T cells (control) were used as effector cells.

[0043] Effector cells (1×10 5 / wells) and target cells (1×10 5 / well) were inoculated in a 96-well plate, 100 μL / well, and divided into five groups. The specific groups are as follows: Experimental group A: EGFRvⅢ-GRP78-CAR-T cells were co-cultured with U87 MG cells; Experimental group B: EGFRvⅢ-GRP78 unoptimized-CAR-T cells co-cultured with U87 MG cells; Experimental group C: EGFRvⅢ-CAR-T cells were co-cultured with U87 MG cells; Experimental group D: GRP78-CAR-T cells were co-cultured with U87 MG cells; Control group: T cells were co-cultured with U87 MG cells.

[0044] Place in a 5% CO2, 37°C incubator for co-culture. After 24 hours, add 10uL of CCK-8 to each well. After incubation for another 2 hours, use a microplate reader to detect at 450nm wavelength, read the OD value, and calculate the cell killing rate. The results are as follows: Figure 4 As shown in Table 3: Table 3 Killing rate of target cells by CAR-NK cells

[0045] Compared with the killing rate of the control group (T cells) (19.2%), the killing rate of CAR-T cells in the experimental group was 71.5%-97.8%, and there was a significant difference, which shows that the CAR designed for GBM antigens (EGFRvⅢ, GRP78) of the present invention can induce cells to produce a strong immune response, has specific cytotoxic activity against glioblastoma cell lines (U87 MG), and has a strong tumor killing ability.

[0046] Compared with single-target CAR-T cells (experimental groups C and D), dual-target CAR-T cells (experimental groups A and B) have a higher killing rate for tumor cells, which indicates that dual-target CAR has stronger targeting, can better eliminate tumor cells, reduce tumor antigen escape, and further enhance the ability of CAR-T cells to kill tumors, making them have stronger anti-tumor activity, and improving the efficacy of EGFRvIII (or GRP78) targeting strategy in the treatment of GBM.

[0047] In addition, compared with experimental group B (83.5%), the cell killing rate of experimental group A (97.8%) was higher, which indicates that after codon optimization, the GRP78scFv nucleic acid sequence can improve the killing rate of dual-target CAR-T cells against tumor cells, making it have stronger anti-tumor activity.

Claims

1. A dual-target chimeric antigen receptor, characterized in that: The dual-target chimeric antigen receptor includes EGFRvⅢscFv and GRP78 scFv; the nucleotide sequence of the EGFRvⅢ scFv is shown in SEQ ID NO.2; the nucleotide sequence of the GRP78 scFv is shown in SEQ ID NO.

4.

2. A dual-target chimeric antigen receptor according to claim 1, characterized in that: The dual-target chimeric antigen receptor is connected in sequence by the following modules: CD8 signal peptide, EGFRvⅢ scFv, Linker, GRP78 scFv, CD8 Hinge region, CD8 transmembrane region, CD28 co-stimulatory region, 4-1BB co-stimulatory region, and CD3ζ signal transduction region.

3. A dual-target chimeric antigen receptor according to claim 2, characterized in that: The nucleotide sequence of the CD8 signal peptide is shown in SEQ ID NO.1; the nucleotide sequence of the Linker is shown in SEQ ID NO.3; the nucleotide sequence of the CD8 Hinge region is shown in SEQ ID NO.5; the nucleotide sequence of the CD8 transmembrane region is shown in SEQ ID NO.6; the nucleotide sequence of the CD28 co-stimulatory region is shown in SEQ ID NO.7; the nucleotide sequence of the 4-1BB co-stimulatory region is shown in SEQ ID NO.8; and the nucleotide sequence of the CD3ζ signaling region is shown in SEQ ID NO.

9.

4. A dual-target CAR-T cell, characterized in that: The CAR-T cells are obtained from the chimeric antigen receptor modified T cells according to claim 1.

5. Use of the chimeric antigen receptor according to any one of claims 1 to 3 in the preparation of a medicine for treating glioblastoma.

6. Use of the CAR-T cells according to claim 4 in the preparation of medicines for treating glioblastoma.

Citation Information

Patent Citations

  • Transgenic lymphocytes co-expressing anti-EGFRvIII chimeric antigen receptor and immune checkpoint inhibitory molecule and their applications

    CN106967685B

  • Chimeric antigen receptor-modified monocyte extracellular vesicle analogs, preparation methods and applications

    CN115957335B

  • Anti AFP (alpha-fetoprotein) CAR-T (chimeric antigen receptor T) cell, preparation method thereof and application of cell

    CN107254447A

  • Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders

    CN110678198A

  • Anti-PD-1 double-target CAR-NK cell and application thereof

    CN116555188A